Myasthenia Gravis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 18 years of age or older
• You have been diagnosed with generalized Myasthenia Gravis (a muscle weakness condition), confirmed by medical records, a physical examination, and a specific blood test showing certain antibodies (AChR-Abs)
• You have received more than one round of a blood-filtering treatment (called plasma exchange/PLEX) or an intravenous antibody infusion treatment (IVIg) as part of your care
• Your muscle weakness condition has been classified as a severe level (class IV or V) by medical standards at the time of your ICU admission
• You have already been treated with at least one standard medication used for Myasthenia Gravis
• You are receiving a specific medication called Ravulizumab during your ICU stay, after plasma exchange or IVIg treatment, and this has been approved by specialists from a French rare disease medical network (FILNEMUS)
• You are able to understand and sign a consent form agreeing to take part — if muscle weakness prevents you from signing, a trusted witness may sign on your behalf
• You are willing and able to attend scheduled appointments and follow the study plan
• You are covered by a European social security/health insurance system
• You agree to take steps to prevent a serious bacterial infection called meningococcal disease, through vaccination and/or preventive antibiotics as recommended locally
• You have no medical reason preventing you from taking anti-C5 treatment (the type of drug used in this trial)
• You have no medical reason preventing you from taking antibiotics

Who may not be able to join:

• You have an active infection, or another condition causing muscle weakness, a known immune deficiency (IgA deficiency), active kidney or liver disease, significant heart disease, or a blood-thickening disorder
• You currently have any form of cancer
• You have antibodies in your blood other than the specific AChR antibodies (having anti-titin antibodies alongside AChR antibodies is permitted — confirm with trial site)
• You have a tumour of the thymus gland (called a thymoma)
• You have another health condition that the study doctor believes could interfere with the trial
• You have a positive pregnancy test (women of childbearing age will be tested)
• You have a mental health condition, dementia, or other condition that, in the study doctor's opinion, may affect your ability to understand or follow the study
• You have received a live vaccine within the past 6 weeks
• You do not wish to take part in the study
• You are legally protected or under guardianship in a way that prevents participation in a clinical study under French law
• You have a known allergy or sensitivity to the study drug or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.